Japan Domestic Flights Scheduled for Recovery in Q1 2022: Cirium Survey Reveals Sapporo and Okinawa as Top Destinations
The majority of Japanese travelers intend to take to the skies again, with 80% planning to travel in the next 12 months for leisure purposes (83%) and to domestic destinations, according to the new Cirium Traveler Intelligence Report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006033/en/
Aviation analytics company Cirium records a noticeable increase in intention to travel across other markets surveyed, while travelers in Japan continue to be wary of the potential risks from COVID-19.
International travel is likely to remain difficult, however, there are encouraging indicators of recovery in Japanese domestic markets. Cirium data shows domestic traffic in Japan at 54% of 2019 levels, above the 49% average seen across APAC domestic markets excluding China.
Additionally, Cirium schedules data shows Japan is projected to reach 93% of 2019 Q1 traffic in the first quarter of 2022.
The recovery of international flights continues to be slow, but domestic traffic is recovering to pre-COVID levels experienced in 2019. According to the Cirium Japan survey, the prefectures of Sapporo and Okinawa are the most popular destinations for domestic travel, followed by Tokyo, Fukuoka and Osaka as secondary choices.
Jeremy Bowen, Cirium CEO, said: “The challenge is for airlines to make travelers feel safe about air travel and provide attractive and targeted offers to Japanese holiday makers to encourage travel.”
“At the same time, the tourism sectors needs to work collaboratively in making their region more appealing as a holiday destination and to entice Japan travelers to their prefectures.”
Further insights revealed several factors that could influence the intention to fly. One in five (20%) Japanese respondents will not book a flight until vaccines were fully deployed while almost half (42%) said a decrease in the number of COVID-19 cases will encourage travel.
Once international travel is permitted, nearly half (48%) of the respondents plan to take an international trip, with one-third selecting Europe as their choice of international destination.
The younger age group in Japan (18-29 year olds) expressed the most interest to fly again. Over two-thirds intended to fly within a year (68%) and over half (61%) plan to do so internationally with a preference for the region of East Asia.
When it comes to airline choice, Japanese carriers were clearly preferred with most citing All Nippon Airways as a favourite followed by Japan Airlines, Peach Aviation and Skymark Airlines.
Additional motivating reasons for choosing an airline over another are mandatory mask wearing on flight, requirement for health passports and improved cleaning processes on the aircraft.
The survey was carried out by independent market intelligence firm AudienceNet on behalf of Cirium. The firm interviewed over 2,092 adults in Japan between October 18 to 25, 2021. The margin of error in the reported data did not exceed +/-3% at the 95% confidence level.
Ends
Notes to editors
Click here to read the full Japan Cirium Traveler Intelligence Report.
Additional insights on air travel in the full report include:
- The importance of flying on modern aircraft
- Future use of airport lounges
- Cabin class preferences
- Top destinations in and outside of Japan
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on linkedin or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130006033/en/
Contact information
For media enquiries please contact:
June Lee (APAC) / Rachel Humphries (Global) media@cirium.com
Kyoko Ishida (Japan) at Train Tracks cirium@traintracks.jp
Mindy Wang (China) at Dan Communications shumei.wang@cirium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 14:00:00 EET | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence cohort for early-stage breast cancer,” said William Audeh, M.D., Chief Medical Officer at Agendia. “These results underscore our commitment to generating robust clinical evi
Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 14:00:00 EET | Press release
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an older adult population, a demographic historically underrepresented in clinical trials. Bringing Precision Oncology to Older Individuals with HER2+ Disease Despite the growing number of older adults diagnosed with HER2-positive early breast cancer, optimal treatment strategies remain unclear. Many face increased risks of chemotherapy-related toxicit
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 months,” said Kabir Nath, Chief Executive Officer at Compass Pathways. “We are accelerating commercial launch plans to match this new expected timeline with the goal of advancing our mission of transforming the mental health landscape and how patients living with depression are treated.” Business Highlights COMP360 psilocybin treatment in TRD (Treatment Resistant Depression) Second Phase 3 trial, COMP006, has completed enrollment (n=585) In June 2025, we announced achievement of the 6-week primary endpoint in the first of two phase 3
TELEO Capital Closes Oversubscribed TELEO Capital II at $350 Million Hard Cap4.11.2025 13:00:00 EET | Press release
TELEO Capital Management, LLC (“TELEO”), an operationally focused private equity firm focused on investing in lower middle market enterprise software companies, today announced the final close of TELEO Capital II (“Fund II”) at its hard cap of $350 million in Limited Partner capital commitments. Fund II was oversubscribed and attracted a diverse group of new and existing institutional investors. TELEO executes a time-tested strategy in the lower middle market, leveraging a large purpose-built team and repeatable process designed to deliver consistent, outsized returns. Fund II will continue TELEO’s focus on acquiring mission-critical software divisions of large corporations. TELEO is an ideal partner to large corporate sellers in need of a solution where speed and certainty to close, minimal post-closing distraction risk from shared services agreements, and a commitment to protecting customer and employee relationships are extremely important. “We are honored by the trust our investors
Celonis Partners with Databricks to Power Enterprise AI that Continuously Improves Business Operations4.11.2025 12:00:00 EET | Press release
Celonis, a global leader in Process Intelligence, today announced a partnership with Databricks, the Data and AI company, to provide customers with a seamless, powerful pathway to operationalize AI. The integration leverages Delta Sharing to directly connect the Celonis Process Intelligence Platform with the Databricks Data Intelligence Platform. Delta Sharing is Databricks’ open source approach that enables customers to share live data across platforms, clouds and regions with strong security and governance. This bi-directional integration, powered by Delta Sharing, eliminates the need to move or copy data between the two platforms. It breaks down data silos, reduces data copies, limits synchronization errors, enhances security, and simplifies data governance. With data and process intelligence flowing freely between the two platforms, customers get a continuous learning loop for AI-driven operations. Customers can use Celonis to read live data stored in Databricks and enrich it with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom